About the Authors
- Andreas Franke
-
Affiliation Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany
- Gerhard J. Niederfellner
-
Affiliation Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany
- Christian Klein
-
Affiliations Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany, Pharma Research and Early Development, Roche Glycart AG, Schlieren-Zürich, Switzerland
- Helmut Burtscher
-
* E-mail: helmut.burtscher@roche.com
Affiliation Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany
Competing Interests
All authors are employees of Roche. Rituximab is a marketed Roche product. The aim of the study was to get additional insights into the mode of action of anti-CD20 antibodies, which is obviously also in the interest of the authors' employer. The authors confirm that this does not alter their adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: AF GN CK. Performed the experiments: AF. Analyzed the data: AF. Contributed reagents/materials/analysis tools: AF HB. Wrote the paper: AF GN HB.